Style | Citing Format |
---|---|
MLA | Panahi Y, et al.. "Immunology of Chronic Obstructive Pulmonary Disease and Sulfur Mustard Induced Airway Injuries: Implications for Immunotherapeutic Interventions." Current Pharmaceutical Design, vol. 22, no. 20, 2016, pp. 2975-2996. |
APA | Panahi Y, Jadidiniaragh F, Jamalkandi SA, Ghanei M, Pedone C, Nikravanfard N, Nikravesh F, Sahebkar A (2016). Immunology of Chronic Obstructive Pulmonary Disease and Sulfur Mustard Induced Airway Injuries: Implications for Immunotherapeutic Interventions. Current Pharmaceutical Design, 22(20), 2975-2996. |
Chicago | Panahi Y, Jadidiniaragh F, Jamalkandi SA, Ghanei M, Pedone C, Nikravanfard N, Nikravesh F, Sahebkar A. "Immunology of Chronic Obstructive Pulmonary Disease and Sulfur Mustard Induced Airway Injuries: Implications for Immunotherapeutic Interventions." Current Pharmaceutical Design 22, no. 20 (2016): 2975-2996. |
Harvard | Panahi Y et al. (2016) 'Immunology of Chronic Obstructive Pulmonary Disease and Sulfur Mustard Induced Airway Injuries: Implications for Immunotherapeutic Interventions', Current Pharmaceutical Design, 22(20), pp. 2975-2996. |
Vancouver | Panahi Y, Jadidiniaragh F, Jamalkandi SA, Ghanei M, Pedone C, Nikravanfard N, et al.. Immunology of Chronic Obstructive Pulmonary Disease and Sulfur Mustard Induced Airway Injuries: Implications for Immunotherapeutic Interventions. Current Pharmaceutical Design. 2016;22(20):2975-2996. |
BibTex | @article{ author = {Panahi Y and Jadidiniaragh F and Jamalkandi SA and Ghanei M and Pedone C and Nikravanfard N and Nikravesh F and Sahebkar A}, title = {Immunology of Chronic Obstructive Pulmonary Disease and Sulfur Mustard Induced Airway Injuries: Implications for Immunotherapeutic Interventions}, journal = {Current Pharmaceutical Design}, volume = {22}, number = {20}, pages = {2975-2996}, year = {2016} } |
RIS | TY - JOUR AU - Panahi Y AU - Jadidiniaragh F AU - Jamalkandi SA AU - Ghanei M AU - Pedone C AU - Nikravanfard N AU - Nikravesh F AU - Sahebkar A TI - Immunology of Chronic Obstructive Pulmonary Disease and Sulfur Mustard Induced Airway Injuries: Implications for Immunotherapeutic Interventions JO - Current Pharmaceutical Design VL - 22 IS - 20 SP - 2975 EP - 2996 PY - 2016 ER - |